Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

36.35
-0.3464-0.94%
Volume:15
Turnover:558
Market Cap:19.08M
PE:- -
High:36.35
Open:36.69
Low:36.35
Close:36.69
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:0.08
T/O Rate:0.00%
Dividend:0.11
Dividend Rate:0.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)

TIPRANKS
·
26 mins ago

MEDCAPTAIN's Hong Kong IPO: A Medical Device Empire Built on Acquisitions Faces Multiple Headwinds

Deep News
·
1 hour ago

MS Cuts Novo Nordisk on Growth Prospects, Patent Expiry Risks

Reuters
·
1 hour ago

Growth Without AI: 8 Stock Picks

Dow Jones
·
3 hours ago

The Race for the Next Big Weight-Loss Drug is On-and China Wants In

Dow Jones
·
8 hours ago

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
11 hours ago

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
12 hours ago

Wachtell Dealmaker Jumps to Linklaters to Bolster US Buildout

Reuters
·
Yesterday

Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026

Reuters
·
Yesterday

Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD

TIPRANKS
·
Yesterday

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Yesterday

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Yesterday

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

GlobeNewswire
·
Yesterday

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX

TIPRANKS
·
Yesterday

Johnson & Johnson Receives Ce Marking for Acuvue Oasys Max Reusable Contact Lenses

THOMSON REUTERS
·
Yesterday

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

GlobeNewswire
·
Yesterday

HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating

MT Newswires Live
·
Yesterday

Tellgen's Subsidiary Device Registration Application Accepted by Regulator

Stock News
·
Yesterday

LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices

Stock News
·
Yesterday

'Cut Points' for 2027 Medicare Advantage Plans Look Neutral to Positive, Analysts Say

Reuters
·
Yesterday